Applications of Biospecimens in Oncology Research

Oncology biospecimens are biological materials collected from individuals with cancer, healthy donors, or other relevant comparison populations for research purposes. These include tumor and normal tissue, whole blood and blood-derived components, primary or dissociated cells, and biofluids such as plasma, serum, cerebrospinal fluid, urine, ascites, and pleural fluid.

These specimens enable researchers to investigate the molecular, cellular, immune, and structural characteristics of cancer using patient-derived material.

When available, matched specimens from the same donor, such as primary tumor and adjacent-normal tissue, primary and metastatic tumors, or tumor tissue paired with plasma or serum, provide additional opportunities to study disease biology and biomarker relationships across different specimen types.

• FFPE Tissue: Formalin-fixed, paraffin-embedded tissue preserves tissue morphology and architecture, making it a versatile format for histopathology, immunohistochemistry (IHC), in situ hybridization (ISH), spatial biology, and molecular applications, including next-generation sequencing (NGS).
• Fresh-Frozen and OCT-Embedded Tissue: Frozen tissue supports high-quality DNA, RNA, protein, and metabolite analysis, including genomic, transcriptomic, proteomic, and spatial research. OCT embedding facilitates cryosectioning and frozen-section histology.
• Fresh Tissue: Unfixed tissue collected and processed under appropriate conditions can preserve viable cells for primary-cell isolation, flow cytometry, functional assays, cell culture, tissue dissociation, and development of patient-derived research models.
• Plasma and Serum: Blood-derived specimens support research involving circulating DNA and RNA, proteins, antibodies, extracellular vesicles, metabolites, and other biomarkers. Selection of plasma or serum depends on the analyte and downstream assay.
• PBMCs: Peripheral blood mononuclear cells provide lymphocytes and monocytes for immune profiling, flow cytometry, functional assays, cell culture, and molecular analysis.

Tumor specimens are frequently evaluated alongside nonmalignant controls. Matched adjacent-normal tissue can help reduce donor-to-donor variability, while distant-normal tissue and healthy-donor specimens may provide additional comparison groups. The appropriate control should be selected based on the research objectives and supported by available pathology characterization.

Each application depends on selecting a specimen that contains the relevant biology and is compatible with the downstream method. Clinical annotation and pathology review help determine whether the specimen is an appropriate representation of the disease group, treatment setting, and research question.

Researchers use annotated tumor tissue, blood, and other biofluids to identify molecular or cellular features associated with cancer. Candidate diagnostic biomarkers may help distinguish disease from an appropriate control; prognostic biomarkers may be associated with outcome; and predictive biomarkers may indicate the likelihood of response to a particular intervention. Discovery can begin with a relatively focused set of specimens, but meaningful validation requires independent, well-characterized cohorts with sufficient sample sizes and biological diversity to evaluate reproducibility, assay performance, and clinical relevance.

FFPE sections preserve tissue architecture, allowing researchers to evaluate not only whether a protein or nucleic-acid target is present, but also where it is expressed and which cell populations carry the signal. H&E review supports tissue characterization and region selection. IHC can localize and assess protein expression, while multiplex immunofluorescence can reveal co-expression and spatial relationships among tumor, immune, and stromal cells. Tissue microarrays allow many donor samples to be analyzed under relatively consistent staining conditions, making them useful for biomarker screening and validation.

Plasma and serum support research on circulating biomarkers that may complement tissue-based analysis. Plasma is commonly used for cell-free DNA and circulating tumor DNA, while both plasma and serum can support protein and other biomarker studies depending on the assay. Collection tube, time to processing, centrifugation, storage, and freeze-thaw history can change analyte recovery and background signal. The matrix and preanalytical protocol should therefore be selected and validated for the intended biomarker.

Oncology target research asks whether a molecular feature contributes to cancer biology, is present in the relevant patient population, and can be engaged without unacceptable effects in normal tissue. Comparing tumor tissue with carefully selected nonmalignant tissues can help characterize disease-associated expression and potential on-target, off-tumor risk. Broad tissue panels, IHC, IF, FISH, RNA-based tissue analysis, pathology review, and quantitative image analysis can provide evidence about expression level, prevalence, localization, heterogeneity, and cross-reactivity. Biospecimen data contribute to target validation, but functional studies and other evidence are also required to establish biological relevance.

FFPE and fresh-frozen tumor specimens support a wide range of molecular profiling applications, including next-generation sequencing (NGS), transcriptomics, and proteomics. Fresh-frozen tissue is particularly valuable for workflows requiring high-quality RNA and proteins, while FFPE specimens are widely used for targeted sequencing and other validated molecular assays.

Molecular profiling can reveal differences among tumors, but the resulting data become more valuable when paired with diagnosis, histologic subtype, stage or grade, treatment history, treatment-naive status, pathology findings, and other study-relevant clinical characteristics.

Biospecimens help researchers investigate how tumor cells, immune cells, stroma, and soluble factors interact and how those relationships may change with therapy. Tumor tissue provides spatial and morphological context, while PBMCs, dissociated tumor cells, plasma, serum, and other fluids can support cellular, functional, and soluble-biomarker analyses. Using multiple matched specimen types from the same donor can create a more integrated view when the collection protocol and available volumes allow.

PBMCs and dissociated tumor-cell preparations can be analyzed with flow cytometry and other single-cell methods to characterize immune-cell populations, activation or exhaustion markers, tumor-cell phenotypes, and functional responses. Interpretation depends on cell viability, dissociation or isolation method, cryopreservation, recovery conditions, staining panels, and clinical context.

Tissue sections preserve relationships among tumor cells, infiltrating immune cells, vasculature, fibroblasts, extracellular matrix, and other stromal components. IHC, multiplex IF, FISH, spatial profiling, whole-slide imaging, and quantitative image analysis can reveal cellular neighborhoods, biomarker co-expression, immune infiltration, and intratumoral heterogeneity and spatial relationships that may be obscured when tissue is processed into a bulk lysate or single-cell suspension.

Fresh tumor tissue can provide viable material for primary-cell cultures, organoid development, patient-derived xenograft model development, ex vivo assays, and other patient-derived models. These systems may retain selected molecular and phenotypic features of the source tumor and can support research on drug sensitivity, resistance, combination strategies, and mechanisms of action. Their representativeness depends on specimen quality, model-establishment methods, selection during culture or engraftment, passage history, and ongoing characterization against the source tumor.

Representative FFPE tissues, frozen tissues, cell preparations, plasma, serum, and other biofluids provide matrices for developing and optimizing oncology assays. They can support antibody screening, antigen-retrieval optimization, staining and scoring methods, nucleic-acid extraction, analytical performance evaluation, interference testing, and assessment across expected disease and control populations. For assays intended to support companion diagnostic development, documented specimen provenance, pathology review, preanalytical history, and fit-for-purpose analytical evaluation are especially important. Research assay development is one component of a broader regulated diagnostic-development pathway.

Begin with the research question, target analyte or cell population, downstream assay, required clinical data, and acceptable preanalytical history. The table provides a starting point; project-specific requirements may narrow the choice further. Specimen selection should consider the intended downstream assay, available clinical annotations, collection and processing methods, and study-specific quality requirements.

Cold ischemia time, fixation type and duration, freezing speed, processing delay, storage temperature, freeze-thaw history, shipping conditions, and chain of custody can affect tissue morphology, cell viability, antigenicity, and the yield or integrity of DNA, RNA, proteins, and metabolites. The NCI Best Practices for Biospecimen Resources emphasize documented, consistent procedures for collection, processing, storage, retrieval, and distribution. Study teams should define acceptance criteria and capture enough preanalytical metadata to determine whether specimens are comparable and fit for purpose.

Diagnosis, histologic subtype, stage, grade, pathology review, tumor content, demographics, treatment history, treatment-naive status, molecular findings, collection site, and collection time point can all affect how a specimen should be interpreted. Researchers should identify required versus optional fields before sourcing and confirm how missing data, differing definitions, and pathology discrepancies will be handled. For studies involving matched specimens, consistent donor or case identifiers are also important for linking tissue, blood-derived products, and associated clinical information.

Researchers need specimens that meet scientific requirements while also being collected and distributed under an appropriate ethical, privacy, and quality framework. A sourcing plan should address specimen type and format, donor and disease criteria, pathology, clinical annotation, collection and processing procedures, quantity, timeline, logistics, and documentation.

Existing inventory may be suitable when stored specimens already meet the indication, format, pathology, annotation, quantity, and preanalytical requirements. It can shorten timelines and allow cases to be reviewed before selection. Prospective collection may be needed for rare or narrowly defined indications, fresh viable tissue, specific collection tubes or media, tight processing windows, longitudinal time points, matched specimen sets, or clinical data not captured in existing records. Many projects use both approaches: inventory for an initial phase and prospective collection for gaps or expansion.

In the United States, the applicable requirements depend on the collection context, identifiability, intended use, funding, institutions, and other factors. Ethical sourcing commonly includes informed consent appropriate to the permitted research use, IRB review when required, privacy and confidentiality protections, and documentation of specimen provenance and permitted use. HIPAA applies to covered entities and business associates when protected health information is involved; de-identification is one possible pathway, not a universal synonym for HIPAA compliance.

Quality indicators should be evaluated for their actual scope. ABS Bio states that its biostorage facilities are accredited by the College of American Pathologists and that the company is ISO 9001:2015 certified for all production activities. These credentials support defined aspects of quality and operations, but they do not by themselves establish that a particular specimen is fit for a specific assay.

ABS Bio provides fresh, fresh-frozen, OCT-embedded, and FFPE human tissue; whole blood and blood-derived products such as plasma, serum, and PBMCs; and specialty biofluids from normal and disease-state donors. Its clinical network supports inventory-based sourcing and custom procurement for complex oncology indications, treatment-naive cases, matched specimens, and study-specific clinical or pathology criteria, subject to availability and the collection program. Available specimens may include existing pathology characterization and tumor-content assessment, with additional pathology review and characterization available on demand to meet project-specific requirements.

ABS Bio can combine specimen sourcing with preparation and analytical services, including FFPE processing and sectioning, H&E, pathology review, tissue microarrays, IHC, IF, FISH, multiplex spatial biology, digital pathology and image analysis, flow cytometry and sorting, tissue dissociation, cryopulverization, nucleic-acid isolation, and other cell and tissue workflows. Connecting sourcing and downstream preparation can reduce handoffs and help align specimen selection with the intended analysis.

ABS Bio supports controlled ambient, refrigerated, frozen, ultra-low-temperature, and liquid-nitrogen storage, together with inventory management, chain-of-custody documentation, temperature monitoring, packaging, shipping, and on-demand distribution. Storage and logistics requirements can be incorporated into the project plan to protect specimen integrity from receipt through final delivery.

Discuss your oncology study objectives, specimen formats, donor and disease criteria, clinical annotation, processing requirements, and timeline with ABS Bio. The scientific team can evaluate available inventory, prospective collection, and integrated laboratory-service options and help develop a fit-for-purpose biospecimen strategy.